|
Rigel Assumes Development Responsibility For Inhaled Asthma
BioResearch Online (press release) South San Francisco, CA /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. … |
View full post on asthma – Google News